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Abstract
Study Design: Systematic review.
Objectives: Anterior cervical approach is associated with complications such as dysphagia and airway compromise. In this study,
we aimed to systematically review the literature on the efficacy and safety of corticosteroid administration as a preventive
measure of such complications in anterior cervical spine surgery with fusion.
Methods: Following a systematic literature search of MEDLINE, Embase, and Cochrane databases in July 2016, all comparative
human studies that evaluated the effect of steroids for prevention of complications in anterior cervical spine surgery with fusion
were included, irrespective of number of levels and language. Risk of bias was assessed using MINORS (Methodological Index for
Non-Randomized Studies) checklist and Cochrane Back and Neck group recommendations, for nonrandomized and randomized
studies, respectively.
Results: Our search yielded 556 articles, of which 9 studies (7 randomized controlled trials and 2 non–randomized controlled
trials) were included in the final review. Dysphagia was the most commonly evaluated complication, and in most studies, its
severity or incidence was significantly lower in the steroid group. Although prevertebral soft tissue swelling was less commonly
assessed, the results were generally in favor of steroid use. The evidence for airway compromise and length of hospitalization was
inconclusive. Steroid-related complications were rare, and in both studies that evaluated the fusion rate, it was comparable
between steroid and control groups in long-term follow-up.
Conclusions: Current literature supports the use of steroids for prevention of complications in anterior cervical spine surgery
with fusion. However, evidence is limited by substantial risk of bias and small number of studies reporting key outcomes.
Keywords
cervical vertebrae, diskectomy, intervertebral disc, spinal fusion, steroids

Introduction
The anterior approach to the cervical spine using
Smith-Robinson technique has been commonly used for the
treatment of cervical discopathies.1,2 Although the anterior
approach is believed to be a relatively safe and effective procedure, it has been associated with complications such as dysphagia, dysphonia, airway compromise, and other tissue injuries.3-6
Dysphagia is an unpleasant condition and the most common
complication after anterior cervical approach with a reported
incidence rate of 1% to 79%, starting early in the postoperative
course.7-9 Although the etiology of dysphagia after anterior

cervical spine surgery is not fully understood and there are many
discrepancies in the findings of various studies, some factors
such as local tissue edema, recurrent laryngeal nerve palsy,
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retraction of midline structures during the surgery, and prevertebral soft tissue swelling (PSTS) have been proposed.7,10
Airway compromise is the most serious complication,
associated with pharyngeal edema, as well as hematoma,
angioedema, cerebrospinal fluid leak, and graft displacement.11-16 Although a rare complication, airway compromise
is life-threatening as it could lead to reintubation, tracheostomy, or death.5,17
Corticosteroids are known anti-inflammatory agents that
inhibit the production of inflammatory prostaglandins and cytokines. Since major adverse outcomes after anterior approach are
attributable to pharyngeal edema, it has been assumed that steroids can reduce the incidence of complications.5 The aim of this
systematic review is to evaluate the current evidence regarding
the efficacy and safety of steroids in reducing the complications
of the anterior cervical spine surgery.

Methods
Protocol
This systematic review was designed according to the guidelines of Cochrane Handbook for Systematic Reviews of
Interventions (v. 5.1.0),18 method guideline for systematic
reviews in the Cochrane Back and Neck (CBN) group
[formerly Cochrane Back Review Group (CBRG)],19,20 and the
Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA)21-23 statement.

Eligibility Criteria
We included all studies with a control group including randomized controlled trials (RCTs), controlled clinical trials,
cohort studies, and case-control studies. The target population
was patients of any age who underwent anterior cervical discectomy and fusion (ACDF) or anterior cervical corpectomy
and fusion with one- or multiple-level fusion and received
corticosteroids to prevent complications following the surgery. We excluded studies that used cervical epidural steroid
injections as a diagnostic or therapeutic modality to relieve
radiculopathy or neck pain before the surgery. Animal studies
were also excluded.

Literature Search and Information Sources
We performed a systematic search of the literature on July 10,
2016, using the following electronic databases without any
restrictions on language or date of publications: MEDLINE
(via OvidSP and PubMed), Embase, and Cochrane EBM
(CENTRAL, DSR, and DARE). The complete search strategy
is presented in the appendix. Main search keywords were
“anterior,” “cervical vertebrae,” “cervical,” “neck,”
“intervertebral disc,” “spinal decompression,” “disc degeneration,” “disc displacement,” “disc herniation,”
“radiculopathy,” “myelopathy,” “spinal fusion,” “arthrodesis,”
“discectomy,” “glucocorticoids,” and “steroids.” Unpublished
records were not considered in this review.
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Study Selection
Two authors (SAZ and SBJ) screened all titles and abstracts
independently. Full texts of relevant articles were obtained and
assessed for eligibility. To select the articles, we used a discussion and consensus method at each step, and in case of disagreement, a third reviewer (AA) was consulted. We also
screened the reference lists of included articles and relevant
reviews for possible inclusions.

Data Items and Collection Process
Two independent reviewers (SAZ and SBJ) used a predetermined form to extract the following information: study design,
type of anterior procedure, demographic information, number
of operated levels, inclusion/exclusion criteria for each study,
dosage of the corticosteroid drug, and outcome variables. The
rate of disagreement between the 2 extractors was 1%.
Outcome variables considered in this review were dysphagia/odynophagia, PSTS, airway compromise, length of hospital
stay, steroid-related complications, and fusion rate.

Risk of Bias
The risk of bias was independently assessed by 2 authors (SAZ
and SBJ). Disagreements were resolved with consensus or consultation with a third reviewer (AA). For randomized studies,
we used the 13-item criteria recommended by the Cochrane
Back and Neck (CBN).19,20 This tool contains 5 domains of
bias, including selection bias (criteria 1, 2, and 9), performance
bias (criteria 3, 4, 10, and 11), detection bias (criteria 5 and 12),
attrition bias (criteria 6 and 7), and reporting bias (criterion 8).
There is also a 13th criterion, which covers any potential bias
that is not detected with previous items.20 For nonrandomized
studies, the 12-item criteria of Methodological Index for NonRandomized Studies (MINORS) were used.24 Each criterion is
scored from 0 to 2, and the highest possible score for comparative studies is 24. This tool is proved to be valid and reliable to
evaluate interventional studies.24-26
A pilot test of the risk of bias assessment was performed on a
set of similar articles. The Review Manager (RevMan) Version
5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014) was used for assessment of the risk of bias
and production of related tables.

Data Synthesis
Meta-analysis was not feasible due to the heterogeneity of
studies.

Results
Study Selection
Our search yielded 556 results. Six additional titles were identified through hand-searching of the reference lists (Figure 1).
Of the 31 full-text articles included in the primary screening
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Dysphagia/Odynophagia
In this series of studies, main assessment tools for dysphagia/
odynophagia were the following:
1.

Figure 1. PRISMA flow diagram.

stage, 9 studies (total population: 246 414) were eligible for
further consideration: 7 RCTs16,27-32 and 2 nonrandomized
studies (one cohort33 and one case-control study34). The other
22 articles were excluded because they were case reports,13,35-39
studies without a control group for steroid, 40-45 seminar
abstracts,46-48 reviews,49,50 commentaries,51,52 or studies without
sufficient data on steroid use.53-55 Table 1 shows characteristics
of the included studies.

Risk of Bias
We assessed the risk of bias for 7 randomized studies with CBN
criteria (Figure 2). The 2 extractors primarily disagreed on 14
out of 91 items, all of which were consequently resolved
through discussion and consensus. Allocation concealment,
random sequence generation, and blinding (especially personnel and outcome assessors) were reported in less than 50% of
the trials (Figure 3).
We used MINORS tool for the 2 nonrandomized studies
(Figure 4). Of the total 24 items, 4 items required further discussion and consultation with a third reviewer. Blind evaluation of the endpoints (item 5), loss to follow-up (item 7), and
prospective calculation of the study size (item 8) were not
addressed in both studies.

Outcomes
A detailed summary of the outcome measures is presented in
Table 2.

Bazaz scale, which has 4 grades including none (no
dysphagia), mild (rare episodes of dysphagia with solid
food), moderate (occasional difficulty swallowing
foods such as bread or meat), and severe (frequent dysphagia with liquids and majority of foods).8 The Bazaz
scale has been widely used because of its simplicity;
however, it has never been validated.56 Among included
studies, Song et al30 and Koreckij et al34 used this scale,
and Edwards et al32 applied a modified version.
2. Eating Assessment Tool (EAT-10), a 10-item questionnaire with 0 to 4 points for each item (0 ¼ no problem,
4 ¼ severe problem) and maximum total of 40 points. A
total score greater than 3 is indicative of dysphagia.57
Koreckij et al34 used this tool besides the Bazaz scale.
3. Functional Outcome Swallowing Scale (FOSS) was
administered in one study by Jeyamohan et al.31 This
scale defines different stages for dysphagia ranging
from asymptomatic (stage 0) to non–oral feeding for
all nutrition (stage V).58
4. The Visual Analogue Scale (VAS) was used by Lee
et al16 and Nam et al29 for odynophagia.

Five RCTs reported that intravenous or local corticosteroids
significantly reduce dysphagia after anterior spinal surgery.16,27,30-32 Pedram et al27 performed fiber-optic examination of the oropharynx, the hypopharynx, and the larynx. They
found that pharyngolaryngeal lesions were significantly more
severe in the control group during the first 36 hours after surgery. Lee et al16 reported a lower VAS for odynophagia immediately after surgery and during the first 2 weeks. Song at al30
monitored dysphagia with the Bazaz scale for the first 5 days
after surgery. Although the severity of dysphagia was the same
between the 2 groups in the first day, it was significantly
reduced in the steroid group in postoperative days 2 to 5. Similarly, Edwards et al32 found no significant difference in the
modified Bazaz scale between steroid and control groups in
the first day postoperative, but afterwards, a significant reduction of symptoms occurred in the steroid group, which
remained through the 28 days of follow-up. Jeyamohan
et al,31 in a long-term follow-up (24 months) by FOSS, showed
that the severity of dysphagia is significantly lower in the steroid group during the first month.
Of the 2 remaining RCTs, the one by Emery et al28 did not
have data regarding the swallowing problems, and the other by
Nam et al29 showed no significant difference in VAS scores for
odynophagia between the control, low-dose, and high-dose steroid groups during the first 5 days after surgery. Their study was
the only one that had a population of pure one-level procedure,
while all other studies also included multilevel procedures.
Both the nonrandomized studies found positive effects of
steroids on reducing the incidence or severity of dysphagia.
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Procedure

Prospective RCT ACDF, 2-5 levels
112
 Fusion: carbon- C: 56
fiber cage filled S: 56
with HA,
collagen and
autologous BMA
 Plate fixation: Y

40
C: 20
S: 20

Jeyamohan
(2015)31

Song (2014)30

62
C: 22
S1: 20
S2: 20

Prospective RCT ACDF, 1 level
 Fusion:
allogeneic
cortical bone
and DBM
 Plate fixation: Y
Prospective RCT ACDF, 3-4 levels
 Plate fixation: Y

II: 28
III: 40
IV: 42
V: 2

C
III: 10
IV: 10
S
III: 10
IV: 10

I: 62

C: 55
S: 54

C: 57.3 + 11.0
(29-77)
S: 59.9 + 10.3
(42-74)

C: 48.8 + 7.6
S1: 45.6 + 7.3
S2: 46.9 + 8.6

C: 50.9
S: 54.3

I: 29
II: 21

50
C: 25
S: 25

24 m

3m

5d

21.6 m
(16-32)

(continued)

Dexamethasone (IV), 0.3 mg/
kg before the incision,
followed by 0.15 mg/kg at 8
and 16 h later
Inclusion: radiculopathy or myelopathy Triamcinolone (RF), 40 mg in
a morcellized collagen
requiring 1- or 2-level ACDF
sponge
Exclusion: fusion >3 segments, revision
surgery, corpectomy, trauma,
infection, tumor, general metabolic
diseases (such as rheumatoid
arthritis, diabetes, and chronic heart
and renal diseases)
Dexamethasone (IV), S1: 10,
Inclusion: cervical radiculopathy
5, 5 mg; S2: 20, 10, 10 mg,
requiring single-level ACDF
at 0, 24, and 48 h postop
Exclusion: radiculopathy requiring
ACDF 2 levels, myelopathic
disease, cervical trauma,
corpectomy
Inclusion: degenerative cervical disease Methylprednisolone (IV), 250
mg at 0, 6, 12, and 24 h
requiring multilevel ACDF
postop
confirmed with preoperative plain
radiographs, computed tomography,
and magnetic resonance imaging
Exclusion: trauma other than that
related to the operative procedure
that could influence soft-tissue
swelling
Dexamethasone (IV), 0.2 mg/
Inclusion: age 18 y, cervical
kg intraoperative dose
spondylosis requiring surgical
followed by 0.06 mg/kg
treatment at 2 motion segments,
doses at 6, 12, and 24 h
ventrally approachable vertebral
later
levels
Exclusion: pregnancy, chronic preop
steroid use, coma, incapacitation,
unable to provide consent, allergy
to dexamethasone or related drugs

Inclusion: cervical stenosis with cord
compression at multiple levels

—

II: 24
III: 38
IV: 4

66
C: 31
S: 35

—

Inclusion: patients requiring exclusively Methylprednisolone (IV), 1
mg/kg at 0, 12, and 24 h
anterior operation of the cervical
postop
spine

Steroid

C: 47 + 15.3 (15-88) 36 h
S: 47 + 12.3 (17-83)

FU (Range) Inclusion/Exclusion Criteria

—

Mean Age,
Years (Range)

236
C:158
S:78

Patients/Levels Levels

Nam (2013)29

Pedram (2003)27 Prospective RCT ACDF, ACCF,
Isolated
discectomy,
Isolated fusion
 Plate fixation: Y
Emery (2009)28 Prospective RCT ACCF, 2-4 levels
 Fusion: fibular
strut graft
 Plate fixation: N
Lee (2011)16
Prospective RCT ACDF, 1-2 levels
 Fusion: PEEK
cage filled with
autologous
cancellous bone
 Plate fixation: Y

Author, Year

Table 1. Characteristics of Included Studies.
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Retrospective
case-control

C
II: 10
III: 11
IV: 1
S
II: 10
III: 11
IV: 1

—

—

Age <70
C: 66.8%
S: 69.8%
Age >80
C: 6.2%
S: 5.4%
Age <70
C: 61.8%
S: 60.1%
Age >80
C: 6.3%
S: 5.6%
C: 57.6 + 9.9
S: 55.1 + 7.9

C: 53.5
C
I: 30.4% S: 54.0
II: 69.6%
S
I: 55.6%
II: 33.3%
III: 11.1%

Mean Age,
Years (Range)

3m

3m

1m

Inclusion: ACDF for radiculopathy or
myelopathy
Exclusion: Single-level procedures,
revision surgery, trauma, infection,
tumor, autoimmune-related
diseases (ie, rheumatoid arthritis)

Inclusion: age 18-70 y, elective 1-, 2-, or
3-level ACDF, primary or revision
cases
Exclusion: nondegenerative pathology
(fracture, tumor, infection, etc), 4level ACDF, combined lumbar
fusion surgery, circumferential
surgical approaches
Inclusion: ACDF procedures using
CPT codes 22554, 22551, 22585,
and 63076 in addition to the ICD-9
procedure code 810.2

FU (Range) Inclusion/Exclusion Criteria

Methylprednisolone (RF), 80
mg in a morcellized
collagen sponge

Local injection of
Triamcinolone acetonide, 1
or 10 mg
Methylprednisolone acetate,
20 or 40 or 80 mg

Methylprednisolone (RF), 40
mg/cc in a 1  3 cm
collagen sponge

Steroid

Abbreviations: ACCF, anterior cervical corpectomy and fusion; ACDF, anterior cervical discectomy and fusion; BMA, bone marrow aspirate; BMP, bone morphogenetic protein; C, control/sham/placebo group; CPT,
Current Procedural Terminology; d, day(s); DBM, demineralized bone matrix; FU, follow-up; h, hour(s); HA, hydroxyapatite; ICD-9, International Classification of Disease, 9th Revision; IV, intravenous; m, month(s); N, no;
PEEK, polyether ether ketone; RF, retropharyngeal; S, steroid group; Y. yes.

ACDF, 2-4 levels
44
 Fusion: Cortical C: 22
allograft packed S: 22
with DBM and
local bone
 Plate fixation: Y

45 754
C: 45 432
S: 322

ACDF, 3 levels

Koreckij
(2016)34

200 000
C: 198 230
S: 1770

Retrospective
cohort

Cancienne
(2016)33

50
C: 23
S: 27

Patients/Levels Levels

ACDF, 1-2 levels

Prospective RCT ACDF, 1-3 levels
 Fusion: PEEK
spacer, local
bone graft, and
BMP-2
 Plate fixation: Y

Edwards
(2016)32

Procedure

Study Design

Author, Year

Table 1. (continued)

Zadegan et al
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Figure 4. Summary of risk of bias for nonrandomized studies (MINORS criteria): review authors’ judgments about each risk of bias items
for each included study. 0: Not reported; 1: Reported but inadequate;
2: Reported and adequate.

Figure 2. Summary of risk of bias for randomized studies (the 13-item
criteria of the Cochrane Back and Neck group): review authors’
judgments about each risk of bias items for each included study. Plus
sign (green): low risk; Minus sign (red): high risk; Question mark
(yellow): unclear risk of bias.

Figure 3. Summary of risk of bias for randomized studies (the 13-item
criteria of the Cochrane Back and Neck group): review authors’
judgments about each risk of bias items across all included studies.

Cancienne et al33 in a cohort of 245 754 patients showed that
incidence of dysphagia is lower within 90 days postoperatively
in patients treated with steroids. However, this finding was only
significant in ACDF 3-level fusion. Koreckij et al34 reported
a significant reduction in severity of dysphagia with EAT-10
and Bazaz scale at 1.5- and 3-month follow-up.

Prevertebral Soft Tissue Swelling
Only 4 of the included studies reported PSTS and there were
variations in their assessment methods. Lee et al16 calculated

the ratio of the anteroposterior diameter of each vertebral body
to the prevertebral soft tissue thickness in lateral radiographs of
cervical spine and reported a mean percentage of PSTS at C3-5
as PSTS index. Koreckij et al34 used the same method; the only
difference was that the PSTS index was calculated for C3-7.
Nam et al29 measured the prevertebral soft tissue density, an
area of the prevertebral soft tissue (in cm2) from the lower
border of C1 to the upper end plate of C7 in lateral radiographs.
Song et al30 measured the diameter of prevertebral tissue (in
mm) in lateral view.
The effect of steroid administration on PSTS was concordant with the findings for dysphagia. Nam et al29 found no
significant difference in PSTS among groups within 5 days
postoperative. Lee et al16 and Song et al30 found significant
reduction in PSTS during the 2-week and 1-week follow-ups,
respectively. Similar to the results for dysphagia, Song et al30
reported a nonsignificant difference just for the first day postoperative and a significant effect afterwards.
The only discordance between the results of dysphagia
assessment and PSTS was reported in the case-control study
by Koreckij et al,34 where they found no significant difference
in PSTS but a significant reduction of dysphagia between the
steroid and control groups.

Airway Compromise
The results for this outcome were very limited and poorly
reported. Emery et al28 used delayed extubation (>1 day) as
an indicator of airway compromise and found no significant
difference between the control and steroid groups. Edwards
et al32 reported no adverse airway events (prolonged intubation, reintubation, or readmission for breathing difficulty) in
the steroid group and only one readmission for breathing difficulty in the control group, which was not statistically significant. Nam et al29 conducted VAS score for dyspnea. Although
they reported no significant effect of steroids on reduction of
dysphagia and PSTS, dyspnea was significantly reduced in the
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27

Lee (2011)16

Emery (2009)

28

Pedram (2003)

Author, Year

VAS (odynophagia)
 Immediately postop
C: 5.3
S: 2.5
P ¼ .000
 4 d postop
C: 4.6
S: 1.5
P ¼ .000
 2 w postop
C: 3.5
S: 1.2
P ¼ .000

Overall: lesions were more frequent in group C,
P < .0001, RR: 1.57 (CI ¼ 1.3-1.9)
—

Objective fiber optic ENT exam for pharyngolaryngeal
lesions, 24-36 h postop:
 Absence of lesion
C: 12 (7.59%)
S: 32 (41%)
P < .0001
 Slight
C: 63 (39.8%)
S: 37 (47.4%)
NS
 Moderate
C: 59 (37.3%)
S: 8 (10.2%)
P < .0001
 Severe
C: 22 (13.9%)
S: 1 (1.2%)
P < .0001
 Very severe
C: 2 (1.26%)
S: 0 (0%)
P < .0001

Subjective unpleasant sensation during swallowing,
odynophagia, dysphagia or impaired swallowing
during postop:
C: 130 (82.3%)
S: 56 (71.8%)
NS

Dysphagia/Odynophagia

Table 2. Summary of Findings.

PSTSI in C3-C5 on RG
 Immediately postop
C: 74.3%
S: 58.2%
P ¼ .004
 2 d postop
C: 84.1%
S: 57.9%
P ¼ .000
 4 d postop
C: 82.9%
S: 56.3%
P ¼ .000
 2 w postop
C: 51.4%
S: 44.9%
P ¼ .036

—

—

Prevertebral Soft Tissue
Swelling

Delayed extubation (>1 day)
C: 6 (19.3%)
S: 5 (14.2%)
NS, P ¼ .22
—

Respiratory distress
C: 2 (both had a revision
surgery for drainage of
cervical hematoma)
S: 0

Airway Compromise

—

C: 4.645 d
S: 4.371 d
NS, P ¼ .47

—

Length of Hospital
Stay

Steroid-Related
Complications

—

—

—

—

C: 88 (55%), 66 (41.7%) local nebulization of —
a corticosteroid, 22 (13.9%)
methylprednisolone IV
S: 0
P < .0001

Postoperative Steroid Need

(continued)

With RG and CT
scan at last FU
C: 24 (96%)
S: 25 (100%)

—

—

Fusion
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VAS (odynophagia)
 Immediately postop
C: 1.9 + 0.8
S1: 1.9 + 0.9
S2: 1.9 + 0.7
NS, P ¼ .970
 1 d postop
C: 3.0 + 0.8
S1: 2.9 + 1.0
S2: 3.0 + 0.8
NS, P ¼ .810
 2 d postop
C: 2.5 + 1.0
S1: 2.5 + 0.9
S2: 2.6 + 1.1
NS, P ¼ .936
 3 d postop
C: 2.0 + 1.1
S1: 1.8 + 0.9
S2: 2.0 + 0.9
NS, P ¼ .792
 4 d postop
C: 1.4 + 1.0
S1: 1.2 + 0.7
S2: 1.5 + 0.7
NS, P ¼ .353
 5 d postop
C: 1.0 + 1.0
S1: 0.6 + 0.6
S2: 1.0 + 0.6
NS, P ¼ .078
Dysphagia with Bazaz scale
 1 d postop
C: 20 (100%) svr
S: 19 (95%) svr, 1 (5%) mod
NS, P ¼ .311
 2 d postop
C: 14 (70%) svr, 6 (30%) mod
S: 7 (35%) svr, 13 (65%) mod
P ¼ .027
 3 d postop
C: 8 (40%) svr, 12 (60%) mod
S: 4 (20%) svr, 11 (55%) mod, 5 (25%) mld
P ¼ .041
 4 d postop
C: 4 (20%) svr, 13 (65%) mod, 3 (15%) mld
S: 8 (40%) mod, 12 (60%) mld
P ¼ .005
 5 d postop
C: 14 (70%) mod, 6 (30%) mld
S: 4 (20%) mod, 14 (70%) mld, 2 (10%) none
P ¼ .005

Nam (2013)29

Song (2014)30

Dysphagia/Odynophagia

Author, Year

Table 2. (continued)
Airway Compromise

VAS (dyspnea)
PSTD in C1-C7 on RG
 Immediately postop
 Immediately postop
2
C: 1.4 + 0.7
C: 1629 + 229 cm
2
S1: 1533 + 224 cm
S1: 1.0 + 0.6
2
S2: 1520 + 226 cm
S2: 0.9 + 0.6
NS, P ¼ .237
P ¼ .018
 1 d postop
 1 d postop
C: 1789 + 267 cm2
C: 2.4 + 0.8
S1: 1699 + 258 cm2
S1: 1.8 + 0.7
S2: 1689 + 248 cm2
S2: 1.9 + 0.7
NS, P ¼ .387
P ¼ .043
 2 d postop
 2 d postop
2
C: 1963 + 338 cm
C: 2.5 + 0.9
S1: 2.0 + 0.8
S1: 1865 + 318 cm2
2
S2: 1.9 + 0.7
S2: 1836 + 321 cm
P ¼ .027
NS, P ¼ .419
 3 d postop
 3 d postop
C: 1.6 + 0.7
C: 1966 + 302 cm2
S1: 1.8 + 0.7
S1: 1886 + 282 cm2
2
S2: 1867 + 282 cm
S2: 1.8 + 0.6
NS, P ¼ .501
NS, P ¼ .695
 4 d postop
 4 d postop
2
C: 1853 + 301 cm
C: 1.1 + 0.8
S1: 1776 + 307 cm2
S1: 1.0 + 0.9
S2: 1747 + 251 cm2
S2: 1.0 + 0.7
NS, P ¼ .473
NS, P ¼ .833
 5 d postop
 5 d postop
C: 1706 + 335 cm2
C: 0.6 + 0.7
S1: 1576 + 292 cm2
S1: 0.6 + 0.7
2
S2: 1541 + 305 cm
S2: 0.5 + 0.6
NS, P ¼ .202
NS, P ¼ .653
PSTS summation of
—
C2-C7 on RG
 1 d postop
C: 95.5 + 18.1 mm
S: 84.7 + 17.1 mm
NS, P ¼ .61
 2 d postop
C: 103.5 + 19.2 mm
S: 82.2 + 14.6 mm
P < .001
 3 d postop
C: 103.9 + 21.8 mm
S: 79.4 + 12.7 mm
P < .001
 4 d postop
C: 108.9 + 14.6 mm
S: 76.5 + 12.7 mm
P < .001
 5 d postop
C: 105 + 14.3 mm
S: 78.2 + 13.9 mm
P < .001

Prevertebral Soft Tissue
Swelling

C: 6.0 + 1.02 d
(range 4-7)
S: 5.1 + 0.7 d
(range 4-7)
P ¼ .003

—

Length of Hospital
Stay

—

—

Postoperative Steroid Need

None

—

Steroid-Related
Complications

—

—

(continued)

Fusion
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FOSS
 1 m postop
C: 0.66
S: 0.064
P ¼ .027
 3 m postop
C: 0.261
S: 0.14
NS, P ¼ .445
 6 m postop
C: 0.174
S: 0.2
NS, P ¼ .768
 12 m postop
C: 0.1
S: 0.26
NS, P ¼ .375
 24 m postop
C: 0.041
S: 0.115
NS, P ¼ .333
Number of patients without dysphagia
 1 d postop
C: 7 (30.4%)
S: 4 (14.8%)
NS, P ¼ .305
 4 d postop
C: 3 (13.0%)
S: 16 (59.3%)
P ¼ .001
 7 d postop
C: 5 (21.7%)
S: 16 (59.3%)
P ¼ .010
 14 d postop
C: 7 (30.4%)
S: 18 (66.7%)
P ¼ .022
 28 d postop
C: 6 (26.1%)
S: 15 (55.6%)
P ¼ .047
Dysphagia with modified Bazaz scale
 1 d postop
C: 1.09 + 0.900
S: 1.04 + 0.649
NS, P ¼ .839

Jeyamohan
(2015)31

Edwards
(2016)32

Dysphagia/Odynophagia

Author, Year

Table 2. (continued)
Airway Compromise

—

Adverse airway events:
C: 1 (4.3%), readmission for
breathing difficulty
S: 0
NS, P ¼ .460

 6 d postop
C: 107.8 + 17.0 mm
S: 65.4 + 3.6 mm
P < .001
 7 d postop
C: 100.0 + 19.0 mm
S: 73.5 + 8.7 mm
NS, P ¼ .091
—
Airway compromise rate: 2.7%

Prevertebral Soft Tissue
Swelling

C: 24.42 h
S: 24.97 h
NS, P ¼ .612

—

Length of Hospital
Stay

C: 4 (17.4%)
S: 1 (3.7%)
NS, P ¼ .167

C: 8 (14.3%)
S: 1 (1.8%)

Postoperative Steroid Need

None

—

Steroid-Related
Complications

—

(continued)

CT scan
 6 m postop
C: 60%
S: 39.5%
P ¼ .047
 12 m postop
C: 80%
S: 75%
NS, P ¼ .57
 24 m postop
C: 95.2%
S: 92.7%
NS, P ¼ .572

Fusion

295

—

Prevertebral Soft Tissue
Swelling

Dysphagia with EAT-10
 6w postop
C: 28.6% nl
S: 59.1% nl
NS, P ¼ .067
 3 m postop
C: 42.9% nl
S: 81.8% nl
P ¼ .012

Dysphagia with Bazaz scale
PSTSI in C3-C7 on RG
 6 w postop
 1 d postop
C: 40.9% svr, 27.3% mod, 9.1% mld, 22.7% none
C: 1.19 + 0.24
S: 14.3% svr, 14.3% mod, 9.5% mld, 61.9% none
S: 1.33 + 0.26
P ¼ .008
NS, P ¼ .09
 3 m postop
 6 w postop
C: 23.8% svr, 19% mod, 9.5% mld, 47.6% none
C: 1.58 + 0.70
S: 9.5% mod, 14.3% mld, 76.2% none
S: 1.62 + 0.36
P ¼ .022
2NS, P ¼ .93

 4 d postop
C: 1.74 + 1.05
S: 0.52 + 0.700
P < .001
 7 d postop
C: 1.43 + 1.04
S: 0.56 + 0.751
P < .002
 14 d postop
C: 1.39 + 1.20
S: 0.52 + 0.802
P ¼ .005
 28 d postop
C: 1.35 + 1.11
S: 0.59 + 0.747
P ¼ .012
Incidence of dysphagia after 1-2 level ACDF within
90 days postop
C: 16,582 (8.4%)
S: 133 (7.5%)
NS, P ¼ .198
Incidence of dysphagia after 3-level ACDF within
90 days postop
C: 6631 (14.6%)
S: 29 (9.0%)
P ¼ .005

Dysphagia/Odynophagia

—

—

Airway Compromise

Postoperative Steroid Need

For 3-level ACDF
within 90 days
postop
C: 3 + 2.8 d
S: 2 + 1.3 d
P < .0001
C: 2.2 + 1.9 d
—
S: 1.27 + 0.6 d
P ¼ .03

For 1-2 level ACDF —
within 90 days
postop
C: 2 + 2.2 d
S: 1 + 1.1 d
P < .0001

Length of Hospital
Stay

Fusion

—

—

Combined rates of
—
infection and wound
breakdown within
90 days postop
C: 1.6%
S: 1.7%
NS, P ¼ .717,
OR: 0.9 (CI ¼
0.7-1.3)

Steroid-Related
Complications

Abbreviations: C, control/sham/placebo group; CI, confidence interval; CT, computed tomography; d, day(s); FOSS, Functional Outcome Swallowing Scale; FU, follow-up; h, hour(s); JOA, Japanese Orthopaedic
Association; mld, mild; mod, moderate; m, month; NDI, Neck Disability Index; nl, normal; NS, nonsignificant; OR, odds ratio; PSTD, prevertebral soft tissue density; PSTSI, prevertebral soft tissue swelling index;
RF, retropharyngeal; RG, radiography; RR, relative risk; S, steroid group; SF-12, 12-Item Short-Form Health Survey; svr, severe; VAS, Visual Analogue Scale, w, week(s).

Koreckij
(2016)34

Cancienne
(2016)33

Author, Year

Table 2. (continued)
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steroid group during the first 2 days postoperative. However,
there was no significant difference within the third to the fifth
days postoperative.

Length of Hospital Stay
Both RCTs reporting hospitalization period found no difference between the steroid and control groups.28,32 In contrast,
both nonrandomized studies proved a significantly shorter hospital stay with steroid treatment.33,34

Postoperative Steroid Need
This outcome was defined as the proportion of patients who
required treatment with corticosteroids in the control group or
required extra doses of steroid, additional to the main protocol,
in the steroid group. Three studies reported this outcome to be
higher in the control group compared with the steroid group, as
follows: Pedram et al27 (55% vs 0%, P < .0001), Jeyamohan
et al31 (14.3% vs 1.8%), and Edwards et al32 (17.4% vs 3.7%,
P > .05).

Steroid-Related Complications
Song et al30 followed the patients for 3 months for complications such as peptic ulcer disease or operation site infections
and reported no complications. Likewise, Edwards et al32
found no infection, delayed healing, or diabetes. Combined
rates of infection and wound breakdown were measured by
Cancienne et al33 within 90 days postoperative. There was no
significant difference between the control and steroid groups
(1.6% vs 1.7%, respectively).

Fusion
Only 2 studies reported fusion rate. Lee et al16 observed complete fusion at the latest follow-up (range 16-32 months) in
the lateral radiographs and computed tomography scans of the
patients treated with steroid, while they found one nonunion
in the control group. Jeyamohan et al31 performed computed
tomography scans at 6, 12, and 24 months postoperation. The
fusion rate was significantly lower in the steroid group compared with the control at the 6-month follow-up (39.5% vs
60%, respectively), whereas this difference disappeared at
subsequent follow-ups (at 24 months, 92.7% vs 95.2%,
respectively).

Discussion
In this study, we reviewed the current evidence of steroid use in
anterior cervical spine surgery. Seven RCTs, one case-control
study, and one cohort study were included. The risk of bias
assessment showed that the quality of studies was generally
low, since both the nonrandomized studies were retrograde and
only 2 out of 7 randomized studies had acceptable method of
randomization.
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Dysphagia significantly decreased with corticosteroids. This
finding was confirmed by all studies except the one performed
by Nam et al,29 in which they reported no significant difference
between the control and 2 steroid groups with different doses.
This may be due to their limited inclusion criteria that only
recruited patients with 1-level ACDF and excluded the procedures on 2 or more levels. Cancienne et al33 found significant
effects of steroids only in ACDF 3 levels; in contrast, Lee
et al16 showed that dysphagia was significantly lowered by
steroids in 1- or 2-level ACDF. Despite some controversies,
all studies proved steroids to be beneficial in prevention of
dysphagia after anterior cervical procedures for more than 2
levels of fusion. This discrepancy implies the importance of
steroid trials comparing the outcomes between single- and multilevel procedures. Furthermore, since there is no sufficient
evidence on validity of most of the measures of dysphagia that
were used in these studies, their findings must be interpreted
with caution.
PSTS and airway compromise were reported in less than
50% of studies. PSTS was generally in accordance with findings of dysphagia. Airway compromise is not a common complication and was only reported in 3 studies. There was a vast
variation in assessment methods and the results. Surprisingly,
although Nam et al29 determined no significant effect of steroids on reduction of dysphagia and PSTS, they reported a significantly lower VAS score for dyspnea in steroid group. The
other 2 studies found no significant difference between the
steroid group and controls in their assessments for airway
compromise.28,32
Two major concerns regarding the use of corticosteroids are
steroid-related complications and reduced/delayed fusion. In
those few studies that addressed these outcomes, no complications or long-term reduction of fusion rates were reported.
However, as reported by Jeyamohan et al,31 the fusion rate was
significantly delayed in the steroid group at the 6-month
follow-up. As the current evidence is not enough, it is necessary to appraise the effect of steroids on fusion rate in the
forthcoming studies with long-term designs.
The form, dose, and type of corticosteroid drug, as well as the
methods of outcome evaluation were different in the included
studies. This heterogeneity made the data pooling and metaanalysis impossible. Further clinical trials with appropriate
design and sample size are needed to reach a definite conclusion.

Conclusion
Current literature consistently supports the use of steroids for
prevention of complication such as dysphagia in patients
undergoing anterior cervical spine surgery with fusion. However, these findings are limited by poor methodological quality
of the studies, particularly by the indeterminate quality of the
outcome measurement instruments. Furthermore, lack of comparisons between single- and multilevel surgeries and limited
number of steroid trials that evaluate the fusion rate, airway
compromise, and PSTS are the areas of concern that are recommended to be addressed in future studies.

Zadegan et al
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Appendix

#23. ‘myelo radiculopath*’
#24. discopath*
#25. ‘diskitis’/exp
#26. Diskitis
#27. Discitis
#28. disc* OR disk*
#29. degenerat* OR displace* OR hernia*
#30. disc* OR disk* AND (degenerat* OR displace* OR
hernia*)
#31. ‘anterior spine fusion’/exp
#32. fusion
#33. Arthrodesis
#34. ‘intervertebral diskectomy’/exp OR ‘spinal cord
decompression’/exp OR ‘intervertebral disk’/exp OR ‘intervertebral disk degeneration’/exp OR ‘intervertebral disk
hernia’/exp OR ‘radiculopathy’/exp OR ‘cervical myelopathy’/exp OR discectomy OR diskectomy OR decompression
OR corpectomy OR radiculopath* OR myelopath* OR radiculomyelopath* OR ‘radiculo myelopath*’ OR myeloradiculopath* OR ‘myelo radiculopath*’ OR discopath* OR
‘diskitis’/exp OR diskitis OR discitis OR (disc* OR disk*
AND (degenerat* OR displace* OR hernia*)) OR ‘anterior
spine fusion’/exp OR fusion OR arthrodesis
#35. ‘glucocorticoid’/exp
#36. ‘steroid’/exp
#37. ‘corticosteroid’/exp
#38. ‘dexamethasone’/exp
#39. ‘betamethasone’/exp
#40. ‘hydrocortisone’/exp
#41. ‘cortisone’/exp
#42. ‘prednisolone’/exp
#43. ‘methylprednisolone’/exp
#44. ‘methylprednisolone sodium succinate’/exp
#45. ‘triamcinolone’/exp
#46. ‘triamcinolone acetonide’/exp
#47. ‘budesonide’/exp
#48. ‘fludrocortisone’/exp
#49. ‘fluprednisolone’/exp
#50. ‘paramethasone’/exp
#51. glucocortic*
#52. ‘gluco cortic*’
#53. corticosteroid*
#54. ‘cortico steroid*’
#55. corticoid*
#56. steroid*
#57. Corticotropin
#58. dexamethason*
#59. dexametason*
#60. betamethason*
#61. betametason*
#62. hydrocortison*
#63. cortison*
#64. predniso*
#65. methylpredniso*
#66. ‘methyl predniso*’
#67. triamcinolon*

Search Strategy
PubMed. (Anterior) AND (“Cervical Vertebrae”[Mesh]
OR “Neck”[Mesh] OR cervical OR neck) AND
(“Diskectomy”[Mesh] OR “Decompression, Surgical”[Mesh]
OR “Intervertebral Disc”[Mesh] OR “Intervertebral Disc
Degeneration”[Mesh] OR “Intervertebral Disc Displacement”[Mesh] OR “Discitis”[Mesh] OR “Radiculopathy”[Mesh]
OR “Spinal Cord Diseases”[Mesh] OR discectomy OR diskectomy OR decompression OR corpectomy OR radiculopath* OR
myelopath* OR radiculomyelopath* OR radiculo-myelopath*
OR myeloradiculopath* OR myelo-radiculopath* OR diskitis
OR discitis OR discopath* OR ((disc* OR disk*) AND (degenerat* OR displace* OR hernia*)) OR “Spinal Fusion”[Mesh]
OR “Arthrodesis”[Mesh] OR fusion OR arthrodesis) AND
(“Glucocorticoids”[Mesh] OR “Adrenal Cortex Hormones”[Mesh] OR “Steroids”[Mesh] OR “Dexamethasone”[Mesh]
OR “Betamethasone”[Mesh] OR “Hydrocortisone”[Mesh]
OR “Cortisone”[Mesh] OR “Prednisolone”[Mesh] OR
“Methylprednisolone”[Mesh] OR “Methylprednisolone
Hemisuccinate”[Mesh] OR “Triamcinolone”[Mesh] OR
“Triamcinolone Acetonide”[Mesh] OR “Budesonide”[Mesh]
OR “Fludrocortisone”[Mesh] OR “Fluprednisolone”[Mesh]
OR “Paramethasone”[Mesh] OR glucocortic* OR gluco-cortic*
OR corticosteroid* OR cortico-steroid* OR corticoid* OR steroid* OR corticotropin OR dexamethason* OR dexametason*
OR betamethason* OR betametason* OR hydrocortison* OR
cortison* OR predniso* OR methylpredniso* OR methyl-predniso* OR triamcinolon* OR budesonid* OR fludrocortison*
OR fluprednisolon* OR paramethason*)
Embase
#1. anterior
#2. ‘cervical spine’/exp
#3. ‘neck’/exp
#4. cervical
#5. neck
#6. ‘cervical spine’/exp OR ‘neck’/exp OR cervical OR
neck
#7. ‘intervertebral diskectomy’/exp
#8. ‘spinal cord decompression’/exp
#9. ‘intervertebral disk’/exp
#10. ‘intervertebral disk degeneration’/exp
#11. ‘intervertebral disk hernia’/exp
#12. ‘radiculopathy’/exp
#13. ‘cervical myelopathy’/exp
#14. Discectomy
#15. Diskectomy
#16. Decompression
#17. corpectomy
#18. radiculopath*
#19. myelopath*
#20. radiculomyelopath*
#21. ‘radiculo myelopath*’
#22. myeloradiculopath*
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#68. budesonid*
#69. fludrocortison*
#70. fluprednisolon*
#71. paramethason*
#72. ‘glucocorticoid’/exp OR ‘steroid’/exp OR ‘corticosteroid’/exp OR ‘dexamethasone’/exp OR ‘betamethasone’/exp
OR ‘hydrocortisone’/exp OR ‘cortisone’/exp OR ‘prednisolone’/exp OR ‘methylprednisolone’/exp OR ‘methylprednisolone sodium succinate’/exp OR ‘triamcinolone’/exp OR
‘triamcinolone acetonide’/exp OR ‘budesonide’/exp OR
‘fludrocortisone’/exp OR ‘fluprednisolone’/exp OR ‘paramethasone’/exp OR glucocortic* OR ‘gluco cortic*’ OR
corticosteroid* OR ‘cortico steroid*’ OR corticoid* OR
steroid* OR corticotropin OR dexamethason* OR dexametason* OR betamethason* OR betametason* OR hydrocortison* OR cortison* OR predniso* OR methylpredniso* OR
‘methyl predniso*’ OR triamcinolon* OR budesonid* OR
fludrocortison* OR fluprednisolon* OR paramethason*
#73. anterior AND (‘cervical spine’/exp OR ‘neck’/exp OR
cervical OR neck) AND (‘intervertebral diskectomy’/exp
OR ‘spinal cord decompression’/exp OR ‘intervertebral
disk’/exp OR ‘intervertebral disk degeneration’/exp OR
‘intervertebral disk hernia’/exp OR ‘radiculopathy’/exp
OR ‘cervical myelopathy’/exp OR discectomy OR diskectomy OR decompression OR corpectomy OR radiculopath*
OR myelopath* OR radiculomyelopath* OR ‘radiculo myelopath*’ OR myeloradiculopath* OR ‘myelo radiculopath*’
OR discopath* OR ‘diskitis’/exp OR diskitis OR discitis OR
(disc* OR disk* AND (degenerat* OR displace* OR hernia*)) OR ‘anterior spine fusion’/exp OR fusion OR
arthrodesis) AND (‘glucocorticoid’/exp OR ‘steroid’/exp
OR ‘corticosteroid’/exp OR ‘dexamethasone’/exp OR
‘betamethasone’/exp OR ‘hydrocortisone’/exp OR ‘cortisone’/exp OR ‘prednisolone’/exp OR ‘methylprednisolone’/exp OR ‘methylprednisolone sodium succinate’/exp
OR ‘triamcinolone’/exp OR ‘triamcinolone acetonide’/exp
OR ‘budesonide’/exp OR ‘fludrocortisone’/exp OR ‘fluprednisolone’/exp OR ‘paramethasone’/exp OR glucocortic* OR ‘gluco cortic*’ OR corticosteroid* OR ‘cortico
steroid*’ OR corticoid* OR steroid* OR corticotropin OR
dexamethason* OR dexametason* OR betamethason* OR
betametason* OR hydrocortison* OR cortison* OR predniso* OR methylpredniso* OR ‘methyl predniso*’ OR
triamcinolon* OR budesonid* OR fludrocortison* OR fluprednisolon* OR paramethason*)
OVID
1. Anterior.mp.
2. Cervical Vertebrae/
3. Neck/
4. cervical.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
5. neck.mp. [mp¼title, abstract, original title, name of substance word, subject heading word, keyword heading word,
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protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
6. 2 or 3 or 4 or 5
7. Diskectomy/
8. Decompression, Surgical/
9. Intervertebral Disc/
10. Intervertebral Disc Degeneration/ or Intervertebral Disc
Displacement/
11. Discitis/
12. Radiculopathy/
13. Spinal Cord Diseases/
14. discectomy.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
15. diskectomy.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
16. decompression.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
17. corpectomy.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
18. discitis.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
19. diskitis.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
20. radiculopath*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
21. myelopath*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
22. radiculomyelopath*.mp. [mp¼title, abstract, original
title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier]
23. radiculo-myelopath*.mp. [mp¼title, abstract, original
title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier]
24. myeloradiculopath*.mp. [mp¼title, abstract, original
title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique
identifier]
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25. myelo-radiculopath*.mp. [mp¼title, abstract, original
title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique
identifier]
26. discopath*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
27. disc*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
28. disk*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
29. degenerat*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
30. displace*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
31. hernia*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
32. Spinal Fusion/
33. Arthrodesis/
34. fusion.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
35. arthrodesis.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
36. 27 or 28
37. 29 or 30 or 31
38. 36 and 37
39. 7 or 8 or 9 or 10 or 12 or 14 or 15 or 16 or 17 or 20 or 21
or 22 or 23 or 24 or 25 or 26 or 32 or 33 or 34 or 35 or 38
40. Glucocorticoids/
41. Adrenal Cortex Hormones/
42. Steroids/
43. Dexamethasone/
44. Betamethasone/
45. Hydrocortisone/
46. Cortisone/
47. Prednisolone/
48. Methylprednisolone/
49. Methylprednisolone Hemisuccinate/
50. Triamcinolone/
51. Triamcinolone Acetonide/
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52. Budesonide/
53. Fludrocortisone/
54. Fluprednisolone/
55. Paramethasone/
56. glucocortic*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
57. gluco-cortic*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
58. corticosteroid*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
59. cortico-steroid*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
60. corticoid*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
61. steroid*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
62. corticotropin.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
63. dexamethason*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
64. dexametason*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
65. betamethason*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
66. betametason*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
67. hydrocortison*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
68. cortison*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
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69. predniso*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
70. methylpredniso*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
71. methyl-predniso*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
72. triamcinolon*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
73. budesonid*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
74. fludrocortison*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
75. fluprednisolon*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
76. paramethason*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
77. 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or
50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60
or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or
71 or 72 or 73 or 74 or 75 or 76
78. 1 and 6 and 39 and 77
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